In conclusion, ginsenoside Rg1 inhibits podocyte EMT by inducing autophagy via regulation of the AKT/GSK3β/β-catenin pathway, providing a reasonable basis for its therapeutic use in DN. The gene discussed is AKT1; the disease is liver dysplastic nodule.